Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 14108011 trials

LigaChem Biosciences Inc.

Official website

An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.

As of 2026-10-10, LigaChem Biosciences Inc. has 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2006 and listed on KOSDAQ in 2013, LigaChem Biosciences is a medicinal chemistry-based developer specializing in ADCs (antibody-drug conjugates) and synthetic new drugs. Based on its proprietary ADC platform technology ConjuALL, it holds a pipeline including Caxmotabart Entudotin (LCB14, HER2-ADC), CS5001 (LCB71, ROR1-ADC), LCB73 (CD19-ADC), LCB84 (TROP2-ADC), and LCB97 (L1CAM-ADC), alongside synthetic drug programs such as gram-negative and gram-positive antibiotics, and a medical device/consumables supply business. It has licensed LCB14 to China's Fosun Pharma and Iksuda, CS5001 to China's CStone, LCB84 to Janssen, and LCB97 plus its ADC platform to Japan's Ono Pharmaceutical, securing disclosed contract value of roughly KRW 9.4 trillion in milestones across its new drug pipeline.

Products & technology

  • Medical consumables and devicesSupply of treatment materials to two hospitals in the Seoul metropolitan area

Clinical trials

data.go.kr

11 MFDS clinical trial authorisations · 2013–2023 (Phase 1 8 · Phase 2a 2 · Phase 2 1)

  • Phase 2aLCB01-03712023-07-27

    6 trial sites

  • Phase 2aLCB01-03712021-08-04

    8 trial sites

  • Phase 1LCB01-03712020-10-26

    2 trial sites

  • Phase 1LCB01-03712020-05-06

    2 trial sites

  • Phase 1LCB01-03712016-07-26

    1 trial site

  • Phase 2LCB01-03712016-05-25

    16 trial sites

  • Phase 1LCB01-03712015-07-02

    1 trial site

  • Phase 1KR-334932015-05-11

    1 trial site

  • Phase 1LCB01-03712014-05-07

    1 trial site

  • Phase 1LCB01-03712014-01-10

    1 trial site

  • Phase 1LCB01-03712013-01-17

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 4 more trials

R&D and key agreements

Source: DART corporate disclosure

Caxmotabart Entudotin(LCB14) · HER2-ADC, 유방암 · 임상 1상 및 로슈사 케사일라 대비 임상 3상 진행 중 · Licensed to Fosun Pharma (China) and Iksuda (rest of world excluding China/Korea)

CS5001(LCB71) · ROR1-ADC · 미국·호주·중국 임상 1상, 허가임상 개시 앞두고 있음 · Licensed to China's CStone

LCB73 · CD19-ADC · 미국·유럽 임상 1상 진행 중 · Conducted through Iksuda

LCB84 · TROP2-ADC · 임상 1상 공동 진행 중 · Licensed to Janssen in December 2023

LCB97 · L1CAM-ADC · Two licensing agreements with Japan's Ono Pharmaceutical covering LCB97 and the ADC platform

Key disclosures

KRX KIND via OpenDART
Show 9 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 89 more patents

AI reads

MAA server logs · IP-verified
146
Times AI engines pulled LigaChem Biosciences Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

142
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

15
live 0
Last 7 days
75
live 4
Last 30 days
146
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot84
  • GoogleGoogleOther49
  • PerplexityPerplexityBot6
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for LigaChem Biosciences Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition